Equities

Bioventus Inc

BVS:NSQ

Bioventus Inc

Actions
  • Price (USD)11.35
  • Today's Change-0.16 / -1.39%
  • Shares traded16.21k
  • 1 Year change+197.12%
  • Beta0.8037
Data delayed at least 15 minutes, as of Nov 22 2024 15:11 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments373044
Total Receivables, Net123137125
Total Inventory918562
Prepaid expenses171827
Other current assets, total02.785.28
Total current assets268273263
Property, plant & equipment, net504440
Goodwill, net7.467.46148
Intangibles, net482640695
Long term investments3.142.6229
Note receivable - long term------
Other long term assets------
Total assets8111,3731,226
LIABILITIES
Accounts payable233717
Accrued expenses119113138
Notes payable/short-term debt000
Current portion long-term debt/capital leases283318
Other current liabilities, total5.511228.19
Total current liabilities175304181
Total long term debt367385340
Total debt395418358
Deferred income tax1.212.25134
Minority interest488775
Other liabilities, total4626938
Total liabilities6371,047767
SHAREHOLDERS EQUITY
Common stock0.080.080.08
Additional paid-in capital494491465
Retained earnings (accumulated deficit)(322)(165)(6.6)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.79(0.11)0.18
Total equity174325459
Total liabilities & shareholders' equity8111,3731,226
Total common shares outstanding797875
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.